Valuation: AstraZeneca PLC

Market Cap 290B 446,134B 260B 239B 217B 405B 27,543B 412B 2,850B 1,144B 14,488B 1,089B 1,065B 45,691B P/E 2026 *
24.5x
P/E 2027 * 20.9x
Enterprise Value 310B 477,312B 278B 256B 232B 433B 29,468B 441B 3,049B 1,224B 15,501B 1,165B 1,140B 48,884B EV / Sales 2026 *
4.9x
EV / Sales 2027 * 4.5x
Free-Float
96.62%
Yield 2026 *
1.77%
Yield 2027 * 1.9%
1 day+7.48%
1 week+9.15%
Current month+18.08%
1 month+18.08%
3 months+15.22%
6 months+9.50%
Current year+9.46%
1 week 70,075
Extreme 70075
77,950
1 month 62,475
Extreme 62475
77,950
Current year 60,650
Extreme 60650
80,275
1 year 60,650
Extreme 60650
80,275
3 years 24,288
Extreme 24288
80,275
5 years 5,438.5
Extreme 5438.5
80,275
10 years 214.5
Extreme 214.5
80,275
Manager TitleAgeSince
Chief Executive Officer 66 2012-09-30
Director of Finance/CFO 52 2021-07-31
Chief Operating Officer 55 2015-05-31
Director TitleAgeSince
Director/Board Member 70 1999-04-05
Director/Board Member 66 2012-09-30
Director/Board Member 65 2017-04-26
Change 5-day change 1-year change 3-year change Capi.($)
+7.48%+9.15% - - 290B
+3.19%+11.31%+67.86%+150.58% 1,263B
-0.73%+3.56%+44.51%+85.81% 658B
+1.41%+3.24%+29.22%+107.83% 521B
+0.42%+3.20%+54.15%+67.18% 391B
+2.18%+2.93%+73.30%+45.62% 369B
+1.12%+4.52%+35.30%+58.08% 307B
+6.96%+8.86%+11.27%+36.62% 290B
+1.15%+6.09%+59.59%+77.06% 252B
+3.06%+9.38%+44.11%+119.47% 212B
Average +2.30%+5.90%+46.59%+83.14% 473.55B
Weighted average by Cap. +1.59%+6.60%+50.88%+98.31%

Financials

2026 *2027 *
Net sales 63.3B 97,359B 56.69B 52.15B 47.25B 88.32B 6,011B 89.98B 622B 250B 3,162B 238B 233B 9,971B 67.39B 103,643B 60.35B 55.51B 50.3B 94.03B 6,399B 95.79B 662B 266B 3,366B 253B 248B 10,615B
Net income 11.75B 18,069B 10.52B 9.68B 8.77B 16.39B 1,116B 16.7B 115B 46.33B 587B 44.09B 43.15B 1,851B 13.69B 21,048B 12.26B 11.27B 10.22B 19.1B 1,299B 19.45B 134B 53.97B 684B 51.36B 50.27B 2,156B
Net Debt 20.27B 31,178B 18.16B 16.7B 15.13B 28.28B 1,925B 28.81B 199B 79.95B 1,013B 76.08B 74.46B 3,193B 13.28B 20,422B 11.89B 10.94B 9.91B 18.53B 1,261B 18.87B 130B 52.37B 663B 49.83B 48.77B 2,092B
Projected Income Statement - Annual - AstraZeneca PLC
Logo AstraZeneca PLC
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (99.8%). Net sales break down by treatment area between oncology (42.6%), cardiovascular, renal and metabolic diseases (23%), respiratory and autoimmune diseases (14.7%), and other (19.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (0.2). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (22.9%), the United States (40.8%), Americas (6.1%) and Africa/Asia/Australia (22.8%).
Employees
96,100
Date Price Change Volume
26-10-30 ARS 77,225.00 +7.48% 3,130
26-10-29 ARS 71,850.00 +2.46% 670
26-10-28 ARS 70,125.00 -0.14% 1,098
26-10-27 ARS 70,225.00 -2.40% 1,297
26-10-26 ARS 71,950.00 +1.70% 913
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - AstraZeneca PLC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
187.02USD
Average target price
210.40USD
Spread / Average Target
+12.50%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - AstraZeneca PLC